These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10500476)

  • 1. Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist.
    Schols D
    Verh K Acad Geneeskd Belg; 1999; 61(4):551-64. PubMed ID: 10500476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
    Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
    J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
    Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
    J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
    De Clercq E
    Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds.
    Owen SM; Rudolph D; Schols D; Fujii N; Yamamoto N; Lal RB
    J Med Virol; 2002 Oct; 68(2):147-55. PubMed ID: 12210401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
    Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
    AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
    Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.
    Doranz BJ; Grovit-Ferbas K; Sharron MP; Mao SH; Goetz MB; Daar ES; Doms RW; O'Brien WA
    J Exp Med; 1997 Oct; 186(8):1395-400. PubMed ID: 9334380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
    Arakaki R; Tamamura H; Premanathan M; Kanbara K; Ramanan S; Mochizuki K; Baba M; Fujii N; Nakashima H
    J Virol; 1999 Feb; 73(2):1719-23. PubMed ID: 9882387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
    Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
    Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.
    Björndal A; Deng H; Jansson M; Fiore JR; Colognesi C; Karlsson A; Albert J; Scarlatti G; Littman DR; Fenyö EM
    J Virol; 1997 Oct; 71(10):7478-87. PubMed ID: 9311827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.
    Schols D; Esté JA; Henson G; De Clercq E
    Antiviral Res; 1997 Aug; 35(3):147-56. PubMed ID: 9298754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A study of anti-HIV compounds which interfere the virus entry via coreceptor CXCR4].
    Kanbara K; Fujii N; Nakashima H
    Kansenshogaku Zasshi; 2000 Mar; 74(3):237-44. PubMed ID: 10783578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.
    Glushakova S; Yi Y; Grivel JC; Singh A; Schols D; De Clercq E; Collman RG; Margolis L
    J Clin Invest; 1999 Sep; 104(5):R7-R11. PubMed ID: 10487781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
    Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
    J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
    Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
    Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.